Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.
Overview
- Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd., Duarte, CA USA
- Department of Surgery, City of Hope, 1500 E. Duarte Rd., Duarte, CA USA
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, 1500 E. Duarte Rd., Duarte, CA USA
- Cellular Immunotherapy Program Cancer Center, Massachusetts General Hospital, Boston, MA USA
- Harvard Medical School, Boston, MA USA
Abstract
Glioblastoma is the most aggressive primary brain tumor with no cure, largely because of tumor heterogeneity and immunosuppressive tumor microenvironment. Chimeric antigen receptor (CAR)-T cell therapy is highly effective in blood cancers but exhibits limited efficacy in glioblastoma due to heterogeneous tumor antigen expression, antigen loss and poor persistence of tumor-targeting immune cells in glioblastoma. Here we show a multimodal immunotherapy strategy that integrates engineered immune cells with oncolytic viruses to overcome these barriers. We have developed bispecific CAR-T and CAR-NK cells in combination with oncolytic virus that delivers two tumor antigens to glioblastoma cells for effective CAR targeting. Moreover, oncolytic virus armed with membrane-bound interleukin-15 and interleukin-21 enhances immune cell expansion/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE310003 — at NCBI GEO; found in “Data availability”
Data availability
The RNA-seq dataset has been uploaded to GEO database with GEO# GSE310003 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 11 authors, 2 keywords, 21 MeSH terms, 1 funder, 87 references.
Cite
This paper
Li, J., Chaurasiya, S., Sun, G., Cui, Q., Ye, P., Qin, Y., Zhou, T., Wang, X., Fong, Y., Maus, M. V., & Shi, Y. (2026). Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs. Nature communications, 17(1), 4839. https://
BibTeX
@article{li2026developin
author = {Li, Jia and Chaurasiya, Shyambabu and Sun, Guihua and Cui, Qi and Ye, Peng and Qin, Yue and Zhou, Tao and Wang, Xiuli and Fong, Yuman and Maus, Marcela V and Shi, Yanhong},
title = {{Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs}},
journal = {Nature communications},
year = {2026},
month = apr,
volume = {17},
number = {1},
pages = {4839},
publisher = {Nature Publishing Group},
issn = {2041-1723},
doi = {10.1038/
url = {https://
pmid = {41957020},
pmcid = {PMC13222885}
}
RIS
TY - JOUR
AU - Li, Jia
AU - Chaurasiya, Shyambabu
AU - Sun, Guihua
AU - Cui, Qi
AU - Ye, Peng
AU - Qin, Yue
AU - Zhou, Tao
AU - Wang, Xiuli
AU - Fong, Yuman
AU - Maus, Marcela V
AU - Shi, Yanhong
TI - Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs
T2 - Nature communications
J2 - Nat Commun
PY - 2026
DA - 2026/
VL - 17
IS - 1
SP - 4839
SN - 2041-1723
PB - Nature Publishing Group
DO - 10.1038/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1038/
"type": "article-journal",
"title": "Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs",
"container-title": "Nature communications",
"author": [
{
"family": "Li",
"given": "Jia"
},
{
"family": "Chaurasiya",
"given": "Shyambabu"
},
{
"family": "Sun",
"given": "Guihua"
},
{
"family": "Cui",
"given": "Qi"
},
{
"family": "Ye",
"given": "Peng"
},
{
"family": "Qin",
"given": "Yue"
},
{
"family": "Zhou",
"given": "Tao"
},
{
"family": "Wang",
"given": "Xiuli"
},
{
"family": "Fong",
"given": "Yuman"
},
{
"family": "Maus",
"given": "Marcela V"
},
{
"family": "Shi",
"given": "Yanhong"
}
],
"container-title-short":
"volume": "17",
"issue": "1",
"page": "4839",
"DOI": "10.1038/
"PMID": "41957020",
"PMCID": "PMC13222885",
"ISSN": "2041-1723",
"publisher": "Nature Publishing Group",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
9
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1016/j.cell.2026.05.026 [code]
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.Journal: CellIn common: other condition, 4 references
- [2] doi:10.1016/j.omton.2026.201201
- Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.Journal: Molecular therapy. OncologyIn common: other condition, 4 references
- [3] doi:10.32604/or.2026.079221
- Single-Cell Sequencing Reveals the Heterogeneity of Glioma and Identifies IGFBP2 as A Potential Therapeutic Target.Journal: Oncology researchIn common: other condition, mouse, 3 references
- [4] doi:10.1126/sciadv.aeb1237
- Magnetically actuated nanoantennas for wireless glioblastoma therapy.Journal: Science advancesIn common: other condition, mouse, 3 references
- [5] doi:10.3389/fonc.2026.1927290
- Arylsulfatase D promotes malignant phenotypes in glioblastoma cells and is linked to altered Hippo pathway phosphorylation.Journal: Frontiers in oncologyIn common: other condition, 3 references
- [6] doi:10.1172/jci.insight.198298
- Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma.Journal: JCI insightIn common: other condition, mouse, 2 references
- [7] doi:10.1016/j.xcrm.2026.102967 [code]
- Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas.Journal: Cell reports. MedicineIn common: other condition, 2 references
- [8] doi:10.1038/s41586-026-10641-1 [code]
- Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.Journal: NatureIn common: other condition, mouse, 2 references
- [9] doi:10.1080/2162402x.2026.2656053
- PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.Journal: OncoimmunologyIn common: other condition, mouse, 2 references
- [10] doi:10.1007/s11060-026-05635-y
- From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence.Journal: Journal of neuro-oncologyIn common: other condition, 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.